Group 1 - Chemours Company signed strategic agreements with SRF Limited to enhance its global supply chain and operational flexibility [1][8] - The partnership allows Chemours to access SRF's manufacturing capacity for fluoropolymers and fluoroelastomers, supporting a shift towards higher value applications without upfront capital investment [2][8] - SRF's expertise in complex chemical production is expected to strengthen its position as a trusted manufacturer of advanced materials through this collaboration [3] Group 2 - For Q3 2025, Chemours anticipates a sequential decrease in consolidated net sales by 4-6% and adjusted EBITDA in the range of $175-$195 million [6] - Full-year 2025 sales are projected between $5.9 billion and $6 billion, with adjusted EBITDA expected to be between $775 million and $825 million [7] - Capital expenditures for 2025 are forecasted to be approximately $250 million [7] Group 3 - Chemours' stock has declined by 16% over the past year, compared to a 20.6% decline in the industry [5] - The company currently holds a Zacks Rank of 4 (Sell), while other stocks in the Basic Materials sector, such as CF Industries and Nutrien, have better rankings [8]

Key Takeaways The Chemours Company (CC) reported a net loss of $381 million or $2.54 per share for second-quarter 2025, in contrast to the year-ago quarter's net income of $60 million or 39 cents. Barring one-time items, earnings were 58 cents per share, which beat the Zacks Consensus Estimate of 46 cents. The company reported second-quarter net sales of $1,615 million, reflecting a 4% rise from the previous-year quarter. It also beat the Zacks Consensus Estimate of $1,568.3 million. A gain of 3% in volume ...

Group 1 - Chemours shares have underperformed over the past year, losing over a third of their value [1] - The chemical industry is facing challenges due to lackluster demand [1] Group 2 - The article does not provide specific investment recommendations or advice [2]

Financial Data and Key Metrics Changes - The company reported strong second quarter results, surpassing expectations with improved performance across all three business segments [8] - Adjusted EBITDA margin for the TSS business was 35%, reflecting the strength of the differentiated portfolio [11] - The company anticipates third quarter net sales to decrease 4% to 6% sequentially, with adjusted EBITDA expected to range between $175 million to $195 million [21] Business Segment Performance Changes - TSS business saw net sales of Opteon refrigerants grow 65% year over year, with Opteon now making up 75% of total refrigerants revenues, up from 57% in the prior year [10][12] - TT delivered sequential net sales up 10%, supported by increased volumes of 9% despite operational issues [13][14] - APM's performance reflected a sequential sales increase of 14%, driven by product sales into the data center cable market, with Advanced Materials seeing a 20% sequential sales increase [16][17] Market Data and Key Metrics Changes - The company noted the effects of Chinese producer capacity rationalization, which has provided opportunities in Western markets [15] - The demand for Opteon refrigerants is expected to continue growing in the second half of the year, moderated by typical seasonality [11] Company Strategy and Industry Competition - The company is focused on executing its Pathway to Thrive strategy, with significant progress in resolving legacy litigation and improving operational excellence [23] - The company aims to be the lowest cost manufacturer and is focused on gaining share in fair trade markets [66] Management's Comments on Operating Environment and Future Outlook - Management acknowledged operational challenges but expressed confidence in the team's ability to address these issues and drive long-term improvements [39] - The company expects to deliver adjusted EBITDA of $775 million to $825 million for the full year 2025, with capital expenditures anticipated to approximate $250 million [21][22] Other Important Information - A settlement with New Jersey was reached, resolving all environmental claims related to PFAS, with a net present value of approximately $250 million [7] - The company has established a new agreement with DuPont and Corteva to acquire rights to insurance proceeds, providing approximately $150 million to fund the New Jersey settlement [7] Q&A Session Summary Question: Outlook for the full year and seasonal patterns - Management indicated that while there will be a seasonal decline, strength in TSS and continued execution across businesses will help offset typical seasonal patterns [32] Question: Drivers of TSS performance - Management highlighted that the strong performance was driven by the transition to Opteon and some potential hoarding due to shortages, but confidence remains for continued growth [35] Question: Vulnerability of TT operations - Management reassured that cost-cutting efforts have not impacted operational reliability and emphasized a clear plan to address operational issues [39] Question: APM outage impact - The outage at Washington Works is expected to have a one-time impact of approximately $20 million, with management confident in the business's overall performance [41] Question: Insurance proceeds and liquidity - The $150 million insurance proceeds relate to past claims and will be realized over the next five years to offset payments under the New Jersey settlement [44] Question: Long-term sales growth expectations - Management anticipates greater than 5% sales growth starting in 2026, driven primarily by TSS [48] Question: Competitive dynamics in TiO2 - The company is focused on being the lowest cost manufacturer and gaining share in fair trade markets, with significant capacity taken out of the market [66][75]

Financial Performance - Net sales reached $1615 million in Q2 2025, a year-over-year increase of $61 million [7] - Adjusted EBITDA was $253 million in Q2 2025, up $46 million compared to Q2 2024 [7] - The company reported a net loss of $381 million in Q2 2025, compared to a net income of $60 million in Q2 2024 [7] - Adjusted EPS was $058 in Q2 2025, compared to $038 in Q2 2024 [7] - Free cash flow was $50 million in Q2 2025, a significant increase of $743 million compared to Q2 2024's negative $693 million [7] Segment Performance - TSS (Thermal & Specialized Solutions) net sales increased to $597 million in Q2 2025 [15] - TT (Titanium Technologies) net sales decreased to $657 million in Q2 2025 [15] - APM (Advanced Performance Materials) net sales slightly increased to $346 million in Q2 2025 [15] Strategic Initiatives and Outlook - Opteon Refrigerants in TSS achieved 65% year-over-year net sales growth [6] - The company announced a settlement with the State of New Jersey to resolve environmental claims, with Chemours' discounted share of settlement payments being approximately $250 million [6, 27] - Q3 2025 net sales are expected to decline 4-6% sequentially, with adjusted EBITDA between $175-$195 million [40, 41] - Full year 2025 adjusted EBITDA is projected to be between $775 million and $825 million, with net sales between $59 billion and $60 billion [44]

The reported revenue compares to the Zacks Consensus Estimate of $1.57 billion, representing a surprise of +2.98%. The company delivered an EPS surprise of +26.09%, with the consensus EPS estimate being $0.46. For the quarter ended June 2025, Chemours (CC) reported revenue of $1.62 billion, up 5% over the same period last year. EPS came in at $0.58, compared to $0.38 in the year-ago quarter. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...

Core Viewpoint - Chemours reported quarterly earnings of $0.58 per share, exceeding the Zacks Consensus Estimate of $0.46 per share, and showing an increase from $0.38 per share a year ago, indicating a strong earnings surprise of +26.09% [1] Group 1: Earnings Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - Chemours posted revenues of $1.62 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.98%, compared to $1.54 billion in the same quarter last year [2] - The earnings report reflects a significant improvement in earnings performance compared to the previous quarter, where the expected earnings were $0.19 per share, but the actual was $0.13, resulting in a surprise of -31.58% [1][2] Group 2: Stock Performance and Outlook - Chemours shares have declined approximately 27.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.50 for the coming quarter and $1.47 for the current fiscal year [4][7] - The Zacks Rank for Chemours is currently 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Group 3: Industry Context - The Chemical - Diversified industry, to which Chemours belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Chemours' stock performance [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36794 The Chemours Company (State or other Jurisdiction of Incorporation or Organization) Delaware 46-4845564 (I.R.S. Employer Identification No.) 1007 Market Street, Wilming ...

EXHIBIT 99.1 The Chemours Company Reports Second Quarter 2025 Results Wilmington, Del., August 5, 2025 – The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the second quarter 2025. Key Second Quarter 2025 Results & Highlights 1 "Our results surpassed our expectations for the quarter ...

Group 1 - The article expresses a beneficial long position in the shares of CC and BASFY, indicating a positive outlook on these companies [1] - The author emphasizes the importance of conducting due diligence and research prior to any investment, highlighting the risks associated with short-term trading and options trading [2] - It is noted that past performance is not indicative of future results, and no specific investment recommendations are provided [3]